<DOC>
	<DOCNO>NCT02118415</DOCNO>
	<brief_summary>Targeted Natural Killer ( NK ) cell base adoptive immunotherapy treatment patient Non-Small Cell Lung Cancer ( NSCLC ) radiochemotherapy ( RCT )</brief_summary>
	<brief_title>Targeted Natural Killer ( NK ) Cell Based Adoptive Immunotherapy Treatment Patients With Non-Small Cell Lung Cancer ( NSCLC ) After Radiochemotherapy ( RCT )</brief_title>
	<detailed_description>Patients non-small cell lung carcinoma ( NSCLC ) stage III A III B show least stable disease RCTx enrol clinical trial . The aim study show efficacy adjuvant treatment Hsp70-peptide TKD/IL-2 activate , autologous NK cell follow completion standard radiochemotherapy ( Cisplatin/Vinorelbine ) . Patients randomize 1:1 either interventional study group receive 4 cycle autologous immunotherapy activate NK cell control group ( BSC ) .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>First diagnosis histologically and/or cytologically prove unresectable NSCLC clinically stage III A III B Completion radiochemotherapy longer 8 week ago Progression free accord RECIST criterion first assessment completion RCTx Confirmed presence Hsp70 patient´s tumor ECOG Status ( Appendices ) ≤ 2 Any severe heart disease severe concomitant disease ( ECOG stage &gt; 2 ) NSCLC patient ( stage IIIA/B ) eligible initial surgery confirm consent interdisciplinary tumorboard Patients show ALK positivity activate mutation EGFRTK domain Patients locally advance metastatic nonsmall cell lung cancer predominantly squamous cell histology Receipt immunosuppressive drug include high dose systemic corticosteroid within 3 week study entry . Low dose corticosteroid common treatment option patient suffer COPD exclusion criterium</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>eligible surgery</keyword>
	<keyword>efficacy immunotherapy follow RCTx</keyword>
</DOC>